617 related articles for article (PubMed ID: 27987070)
21. Effectiveness of [
Pougoue Ketchemen J; Njotu FN; Babeker H; Ahenkorah S; Tikum AF; Nwangele E; Henning N; Cleeren F; Fonge H
Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2070-2084. PubMed ID: 38376808
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab labeled to high specific activity with ¹¹¹In by conjugation to G4 PAMAM dendrimers derivatized with multiple DTPA chelators exhibits increased cytotoxic potency on HER2-positive breast cancer cells.
Chan C; Cai Z; Reilly RM
Pharm Res; 2013 Aug; 30(8):1999-2009. PubMed ID: 23615858
[TBL] [Abstract][Full Text] [Related]
23. Multifunctional targeted therapy system based on (99m) Tc/(177) Lu-labeled gold nanoparticles-Tat(49-57)-Lys(3) -bombesin internalized in nuclei of prostate cancer cells.
Jiménez-Mancilla N; Ferro-Flores G; Santos-Cuevas C; Ocampo-García B; Luna-Gutiérrez M; Azorín-Vega E; Isaac-Olivé K; Camacho-López M; Torres-García E
J Labelled Comp Radiopharm; 2013 Nov; 56(13):663-71. PubMed ID: 25196028
[TBL] [Abstract][Full Text] [Related]
24. Preparation of
Kameswaran M; Pandey U; Gamre N; Sarma HD; Dash A
Appl Radiat Isot; 2019 Jun; 148():184-190. PubMed ID: 30974402
[TBL] [Abstract][Full Text] [Related]
25. Antibody-conjugated pH-sensitive liposomes for HER-2 positive breast cancer: development, characterization,
Raikwar S; Yadav V; Jain S; Jain SK
J Liposome Res; 2024 Jun; 34(2):239-263. PubMed ID: 37594466
[TBL] [Abstract][Full Text] [Related]
26. Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.
Costantini DL; McLarty K; Lee H; Done SJ; Vallis KA; Reilly RM
J Nucl Med; 2010 Jul; 51(7):1084-91. PubMed ID: 20554744
[TBL] [Abstract][Full Text] [Related]
27. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
[TBL] [Abstract][Full Text] [Related]
28. Preparation and preclinical evaluation of
Kameswaran M; Gota V; Ambade R; Gupta S; Dash A
J Labelled Comp Radiopharm; 2017 Jan; 60(1):12-19. PubMed ID: 27813128
[TBL] [Abstract][Full Text] [Related]
29. Comparative
Sharma R; Kameswaran M; Dash A
Cancer Biother Radiopharm; 2020 Apr; 35(3):177-189. PubMed ID: 32196365
[No Abstract] [Full Text] [Related]
30. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
Chan C; Fonge H; Lam K; Reilly RM
Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
[TBL] [Abstract][Full Text] [Related]
31. Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer.
Nunes T; Pons T; Hou X; Van Do K; Caron B; Rigal M; Di Benedetto M; Palpant B; Leboeuf C; Janin A; Bousquet G
J Exp Clin Cancer Res; 2019 Jul; 38(1):306. PubMed ID: 31299997
[TBL] [Abstract][Full Text] [Related]
32. Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells.
Truffi M; Colombo M; Sorrentino L; Pandolfi L; Mazzucchelli S; Pappalardo F; Pacini C; Allevi R; Bonizzi A; Corsi F; Prosperi D
Sci Rep; 2018 Apr; 8(1):6563. PubMed ID: 29700387
[TBL] [Abstract][Full Text] [Related]
33. Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.
Abbas N; Bruland ØS; Brevik EM; Dahle J
Nucl Med Commun; 2012 Aug; 33(8):838-47. PubMed ID: 22643311
[TBL] [Abstract][Full Text] [Related]
34. Trastuzumab gold-conjugates: synthetic approach and in vitro evaluation of anticancer activities in breast cancer cell lines.
Curado N; Dewaele-Le Roi G; Poty S; Lewis JS; Contel M
Chem Commun (Camb); 2019 Jan; 55(10):1394-1397. PubMed ID: 30632546
[TBL] [Abstract][Full Text] [Related]
35. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
[TBL] [Abstract][Full Text] [Related]
36. Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
Bhusari P; Vatsa R; Singh G; Parmar M; Bal A; Dhawan DK; Mittal BR; Shukla J
Int J Cancer; 2017 Feb; 140(4):938-947. PubMed ID: 27813061
[TBL] [Abstract][Full Text] [Related]
37. Dose-dependent cell cycle arrest and apoptosis in HER2 breast cancer cells by
Sharma R; Kameswaran M; Pandey U; Dash A
J Cancer Res Ther; 2020; 16(6):1426-1434. PubMed ID: 33342808
[TBL] [Abstract][Full Text] [Related]
38. [
Kondo M; Cai Z; Chan C; Forkan N; Reilly RM
EJNMMI Radiopharm Chem; 2023 Sep; 8(1):24. PubMed ID: 37750937
[TBL] [Abstract][Full Text] [Related]
39. Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
Costantini DL; Villani DF; Vallis KA; Reilly RM
J Nucl Med; 2010 Mar; 51(3):477-83. PubMed ID: 20150272
[TBL] [Abstract][Full Text] [Related]
40. A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice.
Panosa C; Fonge H; Ferrer-Batallé M; Menéndez JA; Massaguer A; De Llorens R; Reilly RM
Nucl Med Biol; 2015 Dec; 42(12):931-8. PubMed ID: 26385534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]